Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,306
  • Shares Outstanding, K 20,630
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,420 K
  • EBIT $ -46 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.58

Options Overview Details

View History
  • Implied Volatility 327.67% ( -232.20%)
  • Historical Volatility 69.86%
  • IV Percentile 96%
  • IV Rank 56.98%
  • IV High 559.87% on 11/20/24
  • IV Low 20.12% on 09/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 557
  • Open Int (30-Day) 1,006

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.56
  • Number of Estimates 2
  • High Estimate -0.54
  • Low Estimate -0.59
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +37.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.78 +34.27%
on 10/23/24
2.78 -14.03%
on 11/14/24
+0.48 (+25.13%)
since 10/22/24
3-Month
1.60 +49.84%
on 10/10/24
2.78 -14.03%
on 11/14/24
+0.26 (+12.21%)
since 08/22/24
52-Week
1.13 +111.50%
on 11/24/23
5.24 -54.39%
on 04/05/24
+1.27 (+112.44%)
since 11/22/23

Most Recent Stories

More News
Protara Therapeutics to Present Interim Data on TARA-002 for Non-Muscle Invasive Bladder Cancer at SUO Annual Meeting

Protara Therapeutics will present interim Phase 2 trial data for TARA-002 in NMIBC at the SUO meeting in December 2024.Quiver AI SummaryProtara Therapeutics, Inc. has announced that interim data from its...

TARA : 2.39 (+4.37%)
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

TARA : 2.39 (+4.37%)
Protara Therapeutics: Q3 Earnings Snapshot

Protara Therapeutics: Q3 Earnings Snapshot

TARA : 2.39 (+4.37%)
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

TARA : 2.39 (+4.37%)
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

TARA : 2.39 (+4.37%)
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

TARA : 2.39 (+4.37%)
Veeva: Fiscal Q2 Earnings Snapshot

Veeva: Fiscal Q2 Earnings Snapshot

TARA : 2.39 (+4.37%)
Protara Therapeutics: Q2 Earnings Snapshot

Protara Therapeutics: Q2 Earnings Snapshot

TARA : 2.39 (+4.37%)
2 Stocks Under $10 Wall Street Says Are 'Strong Buys'

You can spend less and earn significant returns with these two cheap stocks.

TARA : 2.39 (+4.37%)
$SPX : 5,969.34 (+0.35%)
OPT : 3.16 (+0.96%)
Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview

- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents...

TARA : 2.39 (+4.37%)

Business Summary

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an...

See More

Key Turning Points

3rd Resistance Point 2.60
2nd Resistance Point 2.52
1st Resistance Point 2.46
Last Price 2.39
1st Support Level 2.32
2nd Support Level 2.24
3rd Support Level 2.18

See More

52-Week High 5.24
Fibonacci 61.8% 3.67
Fibonacci 50% 3.18
Fibonacci 38.2% 2.70
Last Price 2.39
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar